| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000Ka 4500 |
| 001 |
in00003510708 |
| 006 |
m o d |
| 007 |
cr bn||||||abp |
| 007 |
cr bn||||||ada |
| 008 |
100414s1999 njua ob 001 0 eng d |
| 005 |
20260421165348.1 |
| 019 |
|
|
|a 649534268
|
| 020 |
|
|
|a 9781592597116 (electronic bk.)
|
| 020 |
|
|
|a 1592597114 (electronic bk.)
|
| 020 |
|
|
|z 0896036472
|
| 020 |
|
|
|z 9780896036475
|
| 035 |
|
|
|a (OCoLC)607077217
|z (OCoLC)649534268
|
| 040 |
|
|
|a OCLCE
|b eng
|e pn
|c OCLCE
|d OCLCQ
|d NUI
|d OCLCQ
|d GW5XE
|d OCLCF
|d GW5XE
|d UtOrBLW
|
| 042 |
|
|
|a dlr
|
| 049 |
|
|
|a TXAM
|
| 050 |
|
4 |
|a QR171.I6
|b B55 1999
|
| 050 |
|
4 |
|a RM267
|b .B56 1999
|
| 060 |
|
4 |
|a 1999 C-112
|
| 060 |
|
4 |
|a WC 100
|b B6167 1999
|
| 082 |
0 |
4 |
|a 616/.01
|2 21
|
| 084 |
|
|
|a 44.75
|2 bcl
|
| 245 |
0 |
0 |
|a Biotherapeutic agents and infectious diseases /
|c edited by Gary W. Elmer, Lynne V. McFarland, Christina M. Surawicz.
|
| 264 |
|
1 |
|a Totowa, N.J. :
|b Humana Press,
|c [1999]
|
| 264 |
|
4 |
|c ©1999
|
| 300 |
|
|
|a 1 online resource (xii, 316 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Ch. 1. Quality control and regulatory issues for biotherapeutic agents-- Ch. 2. Mechanisms of action of biotherapeutic agents-- Ch. 3. Pharmacokinetics of biotherapeutic agents-- Ch. 4. Influences on the normal microbial flora-- Ch. 5. Immunological effects of biotherapeutic agents-- Ch. 6. Biotherapeutic agents in the prevention of antibiotic-associated diarrhea-- Ch. 7. Biotherapeutic agents for clostridium difficile-associated disease--
|
| 505 |
0 |
|
|a Ch. 8. Biotherapeutic agents in the management of pediatric diarrheal disease-- Ch. 9. Biotherapeutic agents and adult diarrhea-- Ch. 10. Biotherapeutic agents as therapy for vaginitis-- Ch. 11. Biotherapeutic agents to prevent cystitis in women-- Ch. 12. Risks of biotherapeutic agents-- Ch. 13. Future directions for research on biotherapeutic agents: contribution of genetic approaches on lactic acid bacteria.
|
| 538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
| 583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|2 pda
|5 MiAaHDL
|
| 520 |
|
|
|a In Biotherapeutic Agents and Infectious Diseases, leading investigators active in the discovery, development, and application of this novel class of anti-infective agents concisely review the use of these special microorganisms in treating human disease. Focusing on biotherapeutic entities that have been tested in controlled studies, the prominent experts illuminate the scientific underpinnings of their therapeutic potential, assess their possible risks in the treatment of infectious diseases, and outline the research needed to better define their effectiveness. In addition, they also consider biotherapeutic agents may be genetically engineered for maximum intestinal and vaginal production of bioactive substances in vivo. Biotherapeutic Agents and Infectious Diseases brings together all the evidence needed to understand and capitalize on the considerable promise of this significant new class of biotherapeutic entities. As an alternative to antibiotics that increasingly lead to drug-resistant pathogens, the living microorganisms described in this timely and authoritative book will significantly aid today's clinicians in the prevention and treatment of infectious diseases.
|
| 588 |
|
|
|a Description based on print version record.
|
| 500 |
|
|
|a Electronic resource.
|
| 650 |
|
0 |
|a Intestines
|x Microbiology.
|
| 650 |
|
0 |
|a Microorganisms
|x Therapeutic use.
|
| 650 |
1 |
2 |
|a Communicable Diseases
|x therapy.
|
| 650 |
2 |
2 |
|a Antibiosis
|x physiology.
|
| 650 |
2 |
2 |
|a Probiotics
|x pharmacology.
|
| 650 |
2 |
2 |
|a Probiotics
|x therapeutic use.
|
| 650 |
1 |
7 |
|a Geneesmiddelen.
|2 gtt
|
| 650 |
1 |
7 |
|a Biologische bestrijding.
|2 gtt
|
| 650 |
|
7 |
|a Intestines
|x Microbiology.
|2 fast
|0 (OCoLC)fst00977690
|
| 650 |
|
7 |
|a Microorganisms
|x Therapeutic use.
|2 fast
|0 (OCoLC)fst01019969
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Elmer, Gary.
|
| 700 |
1 |
|
|a McFarland, Lynne V.
|
| 700 |
1 |
|
|a Surawicz, Christina M.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 776 |
1 |
8 |
|i Print version:
|t Biotherapeutic agents and infectious diseases.
|d Totowa, N.J. : Humana Press, ©1999
|w (DLC) 99201903
|w (OCoLC)40909144
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://link.springer.com/10.1007/978-1-59259-711-6
|z Connect to the full text of this electronic book
|t 0
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
|
|
|a MARS
|
| 999 |
f |
f |
|s 1ff2c301-59dc-35a4-8b7d-eb653e0ec8d6
|i 05bb6c32-daac-382f-a315-8a193a172432
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RM267 .B56 1999
|h Library of Congress classification
|
| 998 |
f |
f |
|a RM267 .B56 1999
|t 0
|l Available Online
|